BIDMC Stands Up to Cancer
Lewis Cantley, PhD, Director of the Cancer Center at Beth Israel Deaconess Medical Center will be leading a "Dream Team" looking for potential treatment for breast,ovarian and endometrial cancer.
Cantley, a research pioneer whose discovery of a molecular pathway known as PI3K, one of the most promising avenues for the development of personalized cancer therapies, is leading a team that will receive $15 million in funding from a national coalition called Stand Up To Cancer (SU2C).
A charitable initiative created by the Entertainment Industry Foundation and administered through the American Association for Cancer Research (AACR), SU2C was created one year ago with the goal of getting new cancer treatments to patients in an accelerated timeframe.
Following a rigorous selection process, five scientific groups -- comprised of more than 300 individuals from 20 institutions and headed up by seven leaders, four co-leaders and 27 principal researchers, as well as patient advocacy representatives -- were awarded the three-year grants.
For more details, including a video with Cantley, click here.